Refining the classification of low risk MDS: Retrospective analysis of cytomorphological and histological variables in 138 patients

ER Verburgh, Gregor Verhoef(Universitair Ziekenhuis Leuven), Ruth Achten(Jessa Hospital), Christiane Brusselmans, Michel Delforge(KU Leuven), Louw, B. Marc, P Christiane

Blood

November 1, 2003

Cited by 2

Related Papers

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

|New England Journal of Medicine|2009|821

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

|New England Journal of Medicine|2023|695

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

|The Lancet|2019|636

ALK+ lymphoma: clinico-pathological findings and outcome.

|PubMed|1999|569

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

|New England Journal of Medicine|2023|538